University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Robert Bhisitkul, Ph.D., M.D.

Ophthalmologist

Clinics

Retina and Vitreous Clinic
400 Parnassus Ave, 7th Floor
San Francisco, CA 94143-0344
Phone: (415) 353–2402
Fax: (415) 353–2713

Hours: Monday to Friday, 8 a.m. to 5 p.m.

Conditions & Treatments

More about Robert Bhisitkul

Education

Stanford 1993

Residencies

Massachusetts Eye and Ear Infirmary, Ophthalmology 1996

Fellowships

Massachusetts Eye and Ear Infirmary, Retina 1998

Selected Research and Publications

  1. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON: A Multicenter Cohort Study (SEVEN-UP). Ophthalmology. 2013 Nov; 120(11):2292-9.
  2. Bhisitkul RB, Campochiaro PA, Shapiro H, Rubio RG. Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology. 2013 May; 120(5):1057-63.
  3. Bernards DA, Bhisitkul RB, Wynn P, Steedman MR, Lee OT, Wong F, Thoongsuwan S, Desai TA. Ocular biocompatibility and structural integrity of micro- and nanostructured poly(caprolactone) films. J Ocul Pharmacol Ther. 2013 Mar; 29(2):249-57.
  4. Campochiaro PA, Bhisitkul RB, Shapiro H, Rubio RG. Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology. 2013 Apr; 120(4):795-802.
  5. Haug SJ, Bhisitkul RB. Risk factors for retinal detachment following cataract surgery. Curr Opin Ophthalmol. 2012 Jan; 23(1):7-11.
  6. Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, Adamis AP, Rubio RG, Murahashi WY. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011 Aug; 118(8):1594-602.
  7. Rofagha S, Bhisitkul RB. Management of retained lens fragments in complicated cataract surgery. Curr Opin Ophthalmol. 2011 Mar; 22(2):137-40.
  8. Fung AE, Bhisitkul RB. Safety monitoring with ocular anti-vascular endothelial growth factor therapies. Br J Ophthalmol. 2008 Dec; 92(12):1573-4.
  9. Rofagha S, Day S, Winn BJ, Ou JI, Bhisitkul RB, Chiu CS. Spontaneous resolution of a traumatic cataract caused by an intralenticular foreign body. J Cataract Refract Surg. 2008 Jun; 34(6):1033-5.
  10. Bhisitkul RB, Winn BJ, Lee OT, Wong J, Pereira Dde S, Porco TC, He X, Hahn P, Dunaief JL. Neuroprotective effect of intravitreal triamcinolone acetonide against photoreceptor apoptosis in a rabbit model of subretinal hemorrhage. Invest Ophthalmol Vis Sci. 2008 Sep; 49(9):4071-7.
  11. He X, Hahn P, Iacovelli J, Wong R, King C, Bhisitkul R, Massaro-Giordano M, Dunaief JL. Iron homeostasis and toxicity in retinal degeneration. Prog Retin Eye Res. 2007 Nov; 26(6):649-73.
  12. Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007 Feb; 114(2):246-52.
  13. Bhisitkul RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol. 2006 Dec; 90(12):1542-7.
  14. Bhisitkul RB, Rutar T. Expanding treatment options in age-related macular degeneration. Int Ophthalmol Clin. 2006; 46(4):123-9.
  15. Bhisitkul RB, Keller CG. Development of Microelectromechanical Systems (MEMS) forceps for intraocular surgery. Br J Ophthalmol. 2005 Dec; 89(12):1586-8.
  16. Levin LA, Gottlieb JL, Beck RW, Albert DM, Liesegang TJ, Hoyt CS, Dick A, Bhisitkul R, Schachat AP. Registration of clinical trials. Arch Ophthalmol. 2005 Sep; 123(9):1263-4.
  17. Bhisitkul RB, Gonzalez VH. "Heavy oil" for intraocular tamponade in retinal detachment surgery. Br J Ophthalmol. 2005 Jun; 89(6):649-50.
  18. Bhisitkul RB, Robinson GS, Moulton RS, Claffey KP, Gragoudas ES, Miller JW. An antisense oligodeoxynucleotide against vascular endothelial growth factor in a nonhuman primate model of iris neovascularization. Arch Ophthalmol. 2005 Feb; 123(2):214-9.
  19. Kwok AH, Pereira DS, Bhisitkul RB. Found in translation. Br J Ophthalmol. 2004 Dec; 88(12):1485.
  20. Paskowitz DM, Nune G, Yasumura D, Yang H, Bhisitkul RB, Sharma S, Matthes MT, Zarbin MA, Lavail MM, Duncan JL. BDNF reduces the retinal toxicity of verteporfin photodynamic therapy. Invest Ophthalmol Vis Sci. 2004 Nov; 45(11):4190-6.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.